Support program has roots in Basel
The online program Selfapy supports people suffering from mental health conditions during the coronavirus lockdown. BaselArea.swiss has provided startup help by way of its DayOne initiative.
The regional business promotion organization BaselArea.swiss is implementing numerous measures to support medical innovations by way of its DayOne initiative. In this context, the DayOne Experts event was held back in February, which placed the focus squarely on the issue of mental health. The participants included Professor Gunther Meinlschmidt, Research Director at the Department of Psychosomatic Medicine at the University Hospital Basel, in addition to the Berlin-based startup Selfapy. Following the event in Basel, Meinlschmidt and Selfapy have developed an online course for people suffering from mental health disorders during the COVID-19 lockdown period.
The free Selfapy program begins with an informative talk over the telephone or via email. During the online course, participants receive access to interactive exercises, videos and informative texts. A psychologist supports the participants and answers any questions they might have. In addition, the participants will be assessed personally and receive feedback on their progress.
“We followed the approach of developing a relatively broad service to offer those affected”, comments Meinlschmidt in an interview published on the website of the International Psychoanalytic University Berlin. “It consists of 12 modules into which we poured general knowledge relating to coping mechanisms and resources in the context of catastrophes and mental illnesses, all connected with specific strategies tailored to the current COVID-19 situation”, he adds. The service can be used by anyone aged 18 or over and is aimed at “people who are feeling the strain and want to do something to improve their mental health and feel less stressed during the ongoing pandemic situation.”
Share this article
You might also be interested in
The Japanese conglomerate Yokogawa has established a Swiss subsidiary based at the Switzerland Innovation Park Basel Area. Here, the focus will be on driving forward innovation in the field of biotechnology.Read More
The Werner Siemens Foundation is to invest an additional 12 million Swiss francs in the Miracle project. Researchers at the University of Basel are developing visionary technology for the use of robots in surgery within the framework of this project.Read More
The Basel-based biopharmaceutical company Versameb has successfully closed a seed financing round. Versameb develops therapies on the basis of mRNA sequences and is now seeking to drive forward the clinical development of its platform devised for this.Read More
Two thirds of the value added attributable to the pharmaceutical industry as a whole in Switzerland is generated in the Basel Area, as revealed by an Interpharma report. However, the region also shines in an international comparison. Interpharma CEO René Buholzer regards it as “probably the most productive life sciences location in the world”.Read More
Resistell AG, based in Muttenz in the canton of Basel-Landschaft, has received a grant of up to 2.5 million euros and additional equity capital financing from a European fund with the aim of accelerating innovation. The company is developing the world’s fastest test against antibiotic resistance.Read More
We are happy to present our latest addition to the Switzerland Innovation Park Basel Area: Our site on the Novartis Campus dedicated to digital health provides a focal point to a unique community of digital healthcare experts.Read More